Dynamiclear Clinical Trial

In 2006, Dynamiclear Australia engaged an internationally renowned FDA and EMEA recognized Clinical Research Organization (CRO) named Apothecaries Limited to conduct a Phase III Clinical Study on the Dynamiclear Topical Solution.

The study was conducted on patients suffering from Herpes simplex infections Type I and Type II, under the guidelines of the WHO Clinical Studies Protocol, GCP and ICP.

This multicenter, randomized, prospective, open label study was conducted to evaluate the safety, tolerability and efficacy of Dynamiclear in the treatment of Herpes simplex (Type 1 and 2) in adult patients.

During the study, it was demonstrated that an application of Dynamiclear can be made safely and effectively to oral and genital herpes infections in both males and females, with a significant reduction in symptoms reported after one application. There were no adverse events reported in this study.

In all the efficacy parameters, a significantly higher percentage of patients in the Dynamiclear group were relieved of symptoms after a single application of the treatment by both ITT and PP analysis.

Brief overview of trial results:

24 Hours After One Application

48 Hours After One Application

At the End of the Study Period (7 days)

Detailed information:

Dynamiclear - Phase III Clinical Trial Summary Report (PDF)

FDA Sponsored Research Study on Cupric Ions (key actives in Dynamiclear)

• Reviews from Users of Dynamiclear
• Further technical questions? Please contact our Support Team